Loading...
NPI 1629047436 · Aston, PA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Brookside Clinical Laboratory Inc is a clinical medical laboratory provider located in Aston, Pennsylvania. This profile covers 136 Medicare and 38 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Brookside Clinical Laboratory Inc |
| Address | 2901 Dutton Mill Rd Ste 100 |
| City | Aston |
| State | PA |
| ZIP | 19014 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | March 15, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $10.6M |
| Medicaid | $270.7K |
This provider is overwhelmingly Medicare‑driven: reported lifetime Medicare revenue is $10.6M compared with $270.7K in Medicaid revenue, so Medicare represents the primary revenue stream while Medicaid is a relatively small secondary payer for this entity. The scale difference implies contracting, margins, and operational focus will be driven by Medicare pricing and referral relationships.
Revenue concentration differs sharply between payers: the top three Medicare codes account for 36.4% of Medicare revenue, indicating a moderate concentration in a few high‑value assays, while the top three Medicaid codes make up 59.1% of Medicaid revenue, showing Medicaid receipts are highly concentrated in a very small set of services. This suggests Medicaid income is driven by a narrow set of offerings (notably COVID testing and routine panels) while Medicare supports a broader mix including several high‑value molecular tests.
The provider’s code mix signals a specialty molecular/genetic laboratory with high throughput specimen collection operations. High‑revenue Medicare codes are dominated by sequencing and cancer/genetic panels (examples include 81307, 81317, 81298, 81249, 81238 and 81223), which are technical sequencing assays, while both payers also show large claim counts for specimen collection and travel allowance codes (G0471, P9604, P9603), consistent with mobile or SNF/HHA specimen collection services.
On competitive standing for advanced assays, BROOKSIDE posts above‑typical national volumes for several targeted genetic tests: 81317 and 81298 each rank #5 nationally and sit in the ~92nd percentile, and 81307 ranks in the upper national quartile at #8 (around the 89th percentile). These rankings indicate the lab is a meaningful national participant for specific hereditary cancer and related sequencing assays rather than a low‑volume local provider.
COVID and high‑throughput infectious testing are prominent features of the mix and include outlier activity: Medicare shows 87635 as an "extreme outlier" (100th percentile) with meaningful Medicare revenue, and U0003 is material for both payers (Medicaid U0003 = $118.2K and represents 45.1% of Medicaid revenue; Medicare U0003 = $124.6K). These entries point to substantial investment or capacity in COVID PCR/high‑throughput nucleic acid testing alongside the genetic testing footprint.
Specimen collection and field services are a distinct operational line: Medicare P9604 reports 17.8K claims and $142.6K revenue and Medicaid P9603 is ranked #1 of 9 in‑state (100th percentile), indicating the provider unusually frequently bills travel/mileage and prorated trip charges for homebound or nursing‑home specimen collection. This pattern supports a business model that combines centralized molecular testing with decentralized specimen pickup or mobile phlebotomy.
Routine clinical testing appears as a secondary but present revenue stream, demonstrating service breadth beyond high‑complexity molecular work: Medicare shows large claim counts for panel and common lab codes such as 80053 (9.3K claims, $92.9K revenue, 99th percentile by national rank) and 84443 (5.4K claims, $85.9K revenue, 99th percentile), and Medicaid lists 80053 and several basic chemistry and hematology codes among its top lines. That mix suggests diversification into standard outpatient and institutional lab work in addition to specialty sequencing.
This is an established operator with long tenure in Medicare enrollment, having an NPI enumerated on 2006-03-15 (~20 years ago), which supports interpretation of the above patterns as sustained capabilities (molecular sequencing, high‑throughput infectious testing, and specimen collection) rather than a short‑term or transient billing spike. Longstanding enrollment increases the likelihood the provider has built stable technical capacity and payer relationships to support the observed specialty volumes.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
136 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81307 | The lab analyst performs the technical lab test on a specimen such as blood, to analyze the entire gene sequence for the partner and localizer of BRCA2 (PALB2) gene. | 1,750 | $660 | $1.2M |
| 81317 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the postmeiotic segregation increased 2 [S. cerevisiae], or PMS2 gene. | 1,740 | $660 | $1.2M |
| 81298 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the mutS homolog 6 [E. coli], or MSH6 gene. | 1,750 | $630 | $1.1M |
| 81249 | The lab analyst performs the technical lab test to analyze known the full gene sequence of the glucose–6–phosphate dehydrogenase (G6PD) gene. | 1,410 | $590 | $826.1K |
| 81238 | The lab analyst performs the technical lab test to analyze the full gene sequence of the coagulation factor IX (F9) gene. | 1,370 | $590 | $803.2K |
| 81223 | The lab analyst performs the technical lab test to analyze the entire gene sequence for cystic fibrosis transmembrane conductance regulator gene, also known as CFTR. | 1,410 | $490 | $689.5K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 15,880 | $30 | $540.1K |
| 81162 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the BRCA1, DNA repair–associated gene, also called BRCA1; and BRCA2, DNA repair–associated gene, also called… | 240 | $1,790 | $425.5K |
| 81201 | The lab analyst performs the technical lab test to analyze the entire gene sequence for adenomatous polyposis coli, also known as APC. | 420 | $760 | $320.1K |
| 81279 | The lab analyst performs the technical lab test on a specimen such as blood to analyze specific gene sequences of the JAK2 (Janus kinase 2) gene, such as exons 12 and 13, which may be associated with… | 1,450 | $180 | $264.3K |
Showing 1–10 of 136
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 136 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
136 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 87798 | 8 | 40 | 1,250 | $30 | $1.1M |
| 81307 | 1 | 10 | 1,600 | $660 | $1.1M |
| 81317 | 1 | 10 | 1,590 | $660 | $1.1M |
| 87150 | 3 | 10 | 7,730 | $30 | $1M |
| 81298 | 1 | 10 | 1,610 | $630 | $1M |
| 81249 | 1 | 10 | 1,200 | $590 | $704.4K |
| 81238 | 1 | 10 | 1,160 | $590 | $679.1K |
| 81223 | 1 | 10 | 1,200 | $490 | $585.8K |
| 81162 | 2 | 10 | 260 | $1,790 | $470.3K |
| 81201 | 2 | 10 | 510 | $760 | $390.2K |
Showing 1–10 of 136
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
38 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 4,220 | $30 | $118.2K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 4,330 | $10 | $21.6K |
| 80048 | The lab analyst performs a basic metabolic pane (BMP) test in which he measures the blood level of eight chemicals including total calcium, sodium, potassium, chloride, carbon dioxide, glucose, blood… | 4,940 | $1 | $14.8K |
| 85027 | The lab analyst performs a blood count on the red and white blood cells and platelets also known as thrombocytes. He also determines the hemoglobin, typically by spectrophotometry, and the… | 4,660 | $1 | $14K |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen… | 3,370 | $1 | $13.5K |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 11,500 | $1 | $11.5K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 3,610 | $1 | $10.8K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 1,730 | $10 | $10.4K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 350 | $30 | $9.5K |
| 83036 | Sugar in the bloodstream can get attached to the hemoglobin in red blood cells. Once the sugar is attached, it stays there for the lifetime of the red blood cell (around 120 days or over 3 months).… | 2,140 | $1 | $6.4K |
Showing 1–10 of 38
How this provider's Medicaid billing volume and revenue compare to other Pennsylvania providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Pennsylvania median
38 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 45 | 200 | 990 | $70 | $517.5K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 47 | 60 | 110 | $220 | $151.2K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 64 | 70 | 270 | $50 | $108.2K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 134 | 340 | 2,320 | $10 | $88.6K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 49 | 140 | 770 | $10 | $80.7K |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 40 | 40 | 270 | $70 | $63.1K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 123 | 220 | 310 | $20 | $62.7K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 69 | 260 | 690 | $10 | $57.9K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 171 | 450 | 1,220 | $1 | $48K |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 107 | 410 | 320 | $10 | $37.4K |
Showing 1–10 of 38
Other providers in the same ZIP code as Brookside Clinical Laboratory Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Burman's Medical Supplies, Inc. | PA | Durable Medical Equipment & Medical Supplies | $0 | $9.1M |
| William Ware | PA | Internal Medicine Physician | $500.9K | $1.9K |
| Nancy Rist | PA | Internal Medicine Physician | $134.3K | $0 |
| Mcneill Family Pharmacy Inc | PA | Community/Retail Pharmacy | $32.5K | $0 |
| Clare Miller | PA | Nurse Practitioner | $27K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.